Acer Therapeutics (ACER)

Company Profile

acer therapeutics is a biotech company, headquartered in cambridge, ma, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. acer's lead candidate, edviso™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type ehlers-danlos syndrome (veds). ehlers-danlos syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. veds is a subtype characterized by severe arterial dissections, ruptures and early death. complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. median age of death is estimated to be around 50 years. patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the col3a1 gene. there are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the u.s. (pepin 2014). there are no specific pharmacologica

Company profile

Ticker

ACER

Exchange

NASDAQ

Website

acertx.com/

CEO

Christopher Schelling

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

Former names

Opexa Therapeutics, Inc., PHARMAFRONTIERS CORP, PharmaFrontiers Corp., SPORTAN UNITED INDUSTRIES INC

SEC CIK

0001069308

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

760333165

ACER stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

425

Business combination disclosure

31 Aug 23

8-K

Voting and Support Agreement

14 Aug 23

Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

14 Aug 23

8-K

Entry into a Material Definitive Agreement

26 Jun 23

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

7 Jun 23

8-K

Submission of Matters to a Vote of Security Holders

Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update

15 May 23

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

3 May 23

Latest ownership filings

View all

SC 13D/A

TVM Life Science Ventures VI LP

MICHELLE RENEE GRIFFIN

Financial summary

Financial statements Chart ACER financial data

Quarter (USD)	Jun 23	Mar 23	Dec 22	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	1.55 mm	1.55 mm	1.55 mm	1.55 mm	1.55 mm	1.55 mm
Cash burn (monthly)	1.61 mm	1.08 mm	1.43 mm	1.65 mm	1.83 mm	2.66 mm
Cash used (since last report)	4.89 mm	3.27 mm	4.35 mm	5.01 mm	5.58 mm	8.09 mm
Cash remaining	-3.34 mm	-1.72 mm	-2.80 mm	-3.46 mm	-4.03 mm	-6.53 mm
Runway (months of cash)	-2.1	-1.6	-2.0	-2.1	-2.2	-2.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

ACER institutional ownership history Ownership history

9.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	25	27	-7.4%
Opened positions	4	4	–
Closed positions	6	7	-14.3%
Increased positions	2	5	-60.0%
Reduced positions	7	7	–

13F shares	Current	Prev Q	Change
Total value	2.09 bn	3.38 bn	-38.3%
Total shares	2.42 mm	4.59 mm	-47.2%
Total puts	13.10 k	26.50 k	-50.6%
Total calls	1.70 k	2.00 k	-15.0%
Total put/call ratio	7.7	13.3	-41.8%

Largest owners	Shares	Value	Change
Nantahala Capital Management	1.14 mm	$1.05 bn	-5.5%
Vanguard	415.07 k	$383.27 mm	0.0%
Hudson Bay Capital Management	274.30 k	$253.29 mm	NEW
Anson Funds Management	129.80 k	$119.85 mm	0.0%
Renaissance Technologies	102.55 k	$95.00 k	-8.3%
Geode Capital Management	96.33 k	$88.95 mm	0.0%
BLK Blackrock	76.77 k	$70.89 mm	-25.4%
Hunter Associates Investment Management	60.00 k	$55.00 k	+215.8%
STT State Street	53.04 k	$48.97 mm	-3.4%
Two Sigma Securities	24.61 k	$22.73 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	0.00	-2.20 mm	EXIT
Hudson Bay Capital Management	274.30 k	+274.30 k	NEW
Meridian Wealth Management	0.00	-106.25 k	EXIT
GS Goldman Sachs	0.00	-87.99 k	EXIT
Nantahala Capital Management	1.14 mm	-66.71 k	-5.5%
Hunter Associates Investment Management	60.00 k	+41.00 k	+215.8%
BLK Blackrock	76.77 k	-26.20 k	-25.4%
Two Sigma Securities	24.61 k	+24.61 k	NEW
Two Sigma Investments	0.00	-18.09 k	EXIT
Tower Research Capital	12.72 k	+11.81 k	+1297.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ACER insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Mar 23	Jason Amello	Stock Option Common Stock	Grant	Acquire A	No	No	1.67	20,000	33.40 k	20,000
14 Mar 23	Steve Aselage	Stock Option Common Stock	Grant	Acquire A	No	No	1.67	20,000	33.40 k	20,000
14 Mar 23	Jefferson E Davis	Employee Stock Option Common Stock	Grant	Acquire A	No	No	1.67	30,000	50.10 k	30,000
14 Mar 23	Dunn John Michael	Stock Option Common Stock	Grant	Acquire A	No	No	1.67	20,000	33.40 k	20,000
14 Mar 23	Michelle Renee Griffin	Stock Option Common Stock	Grant	Acquire A	No	No	1.67	20,000	33.40 k	20,000